Case Study: A First-In-Class Peptide Drug Conjugate (PDC) Platform Targeting Sortilin (SORT1) Receptor Positive Cancers

Time: 11:00 am
day: Pre-Conference Seminar Day - Track C


  • Understanding why the normal function of a scavenger receptor, SORT1, can be exploited to rapidly transport novel peptide drug conjugates (PDCs) into cancer cells
  • Discussing the over expression of SORT1 in many solid tumours
  • Learn about Thera’s lead PDC candidate, TH1902, across multiple solid tumours
  • Review the potential of this novel SORT1+ platform for future developments